In contrast, pioglitazone, SGLT2 inhibitors, and GLP-1 receptor agonists have shown strong effectiveness in reducing liver fat and resolving MASH, positioning them as promising treatments for MASLD [16]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.